Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

PHASE3CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

October 31, 2009

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Bendamustine HCl

Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.

Trial Locations (40)

10021

Weill Cornell Cancer Care Center, New York

14263

Roswell Park Cancer Institute, Buffalo

14623

Interlakes Foundation, Inc., Rochester

14642

University of Rochester Medical Center, James P. Wilmot Cancer Center, Rochester

20007

Georgetown University Medical Center, Washington D.C.

22908

University of Virginia Cancer Center, Charlottesville

27710

Duke University School of Medicine, Durham

35233

University of Alabama Birmingham, Birmingham

37203

Sarah Cannon Research Institute, Nashville

38138

The West Clinic/ACORN, Memphis

40536

Markey Cancer Center, University of Kentucky Medical Center, Lexington

44195

The Cleveland Clinic Foundation Taussig Cancer Center, Cleveland

46202

Indiana Oncology Hematology Consultants, A Division of AHN, Indianapolis

48109

University of Michigan Cancer Center, Ann Arbor

48202

Henry Ford Health System, Detroit

53792

University of Wisconsin, Madison

60612

Rush University Medical Center, Chicago

63110

Washington University School of Medicine in St. Louis, St Louis

71130

LSU Health Sciences Center, Feist Weiller Cancer Center, Shreveport

76012

Arlington Cancer Center, Arlington

80010

University of Colorado Cancer Center, Aurora

85724

Arizona Cancer Center, Tucson

87131

University of New Mexico Cancer Research and Treatment Center, Albuquerque

89135

Nevada Cancer Institute, Las Vegas

90033

USC/Norris Cancer Hospital, Los Angeles

90211

Tower Hematology and Oncology Medical Group, Beverly Hills

92093

Moores UCSD Cancer Center, La Jolla

92662

Comprehensive Cancer Center - Desert Regional Medical Center, Palm Springs

94305

Stanford University Division of Oncology, Stanford

94704

Alta Bates Comprehensive Cancer Center, Berkeley

06520

Yale University School of Medicine, New Haven

02115

Dana Farber Cancer Institute, Boston

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

British Columbia Cancer Agency, Vancouver

B3H 1V7

Queen Elizabeth Health Sciences Centre, Halifax

KIH8L6

Ottawa Hospital - General Campus, Ottawa

H2: 4M1

Hopital Notre-Dame du CHUM, Montreal

H4J 1C5

Hopital du Sacre Couer de Montreal, Montreal

S7N 4H4

Saskatchewan Cancer Center Agency, Saskatoon

00919

Hospital Espanol Auxilio Mutuo, Auxilio Mutuo Cancer Center, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY